Q3 FY2026
Filed Nov 16, 2026Unicycive reports Q3 2026 net loss of $(7.0) million, $(0.25) per share, as the OLC NDA resubmission is accepted with a March 25, 2027 PDUFA date
The filing confirms FDA acceptance of the OLC NDA resubmission with a PDUFA target date of March 25, 2027, and reports $59 million in cash, cash equivalents and marketable securities. Against that, the quarterly net loss widened from $(6.0) million to $(7.0) million, which the company attributes primarily to commercial launch expenses. No revenue is reported.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development (R&D) expense, three months ended September 30, 2026GAAP | $2.2M | – | – |
| General and administrative (G&A) expense, three months ended September 30, 2026GAAP | $6.6M | – | – |
| Other income (expense), three months ended September 30, 2026GAAP | $1.8M | – | – |
| Net loss attributable to common stockholders, basic and diluted, three months ended September 30, 2026GAAP | −$7M | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, three months ended September 30, 2026GAAP | $(0.25) per share of common stock | – | – |
| Cash, cash equivalents and marketable securities, as of September 30, 2026other | $59 million (unaudited) | – | – |
Capital returns
- No share repurchases, dividends or other capital returns are reported in the document.
What drove it
- R&D decreased to $2.2 million from $3.0 million. The company says the decrease was primarily driven by a $1.2 million decrease in development costs, partially offset by a $0.5 million increase in non-cash stock-based compensation.
- G&A increased to $6.6 million from $4.4 million. The company says the increase was primarily driven by a $0.6 million increase in non-cash stock-based compensation, a $0.2 million increase in other labor costs and a $1.4 million increase related to commercial launch preparation.
- Other income was $1.8 million, compared with $1.3 million of income a year earlier. The company attributes it primarily to the change in fair value of the Company's warrant liability.
- The company attributes the increased net loss primarily to an increase in commercial launch expenses.
Concerns
- The net loss widened to $(7.0) million from $(6.0) million a year earlier, and the company attributes this primarily to commercial launch expenses.
- The June 2026 Complete Response Letter cited deficiencies previously identified at the original Drug Product vendor. The resubmission includes CMC data from a new Drug Product manufacturing vendor, whose facility was last inspected by the FDA in March 2024 and received "No Action Indicated" status.
- The company does not know whether the FDA will decide to conduct a pre-approval inspection of the new Drug Product vendor.
- The company states that the resubmitted NDA remains subject to FDA review.
- TDAPA eligibility is the company's belief. The filing states that the determination of OLC's NDA classification rests solely with the FDA and remains subject to the agency's determination at the time of approval, and that TDAPA is subject to meeting applicable CMS requirements.
- No revenue is reported in the document, so the commercial launch expenses are not offset by reported product sales in this filing.
What to watch
- FDA review progress toward the PDUFA target action date of March 25, 2027.
- Whether the FDA decides to conduct a pre-approval inspection of the new Drug Product vendor.
- The outcome of the recent FDA inspection of the original Drug Product vendor, and whether the company aligns with the FDA on a possible shortened review timeline if that facility is found to comply with cGMP.
- Hiring of key commercial leaders, planned for the first quarter of 2027, and the expected hiring of an optimized sales force if OLC is approved.
- CMS confirmation of TDAPA eligibility for OLC, subject to FDA approval.
- Cash runway, which the company describes as extending beyond 2027 including launch costs, against $59 million of cash, cash equivalents and marketable securities.
Balance sheet and cash flow
- As of September 30, 2026, unaudited cash, cash equivalents and marketable securities totaled $59 million.
- The company expects runway beyond 2027, including the anticipated increased expenses related to the launch of OLC should it receive approval.
- Operating cash flow, free cash flow, total assets and stockholders' equity are not reported in the document.
Analysis
Unicycive's third quarter 2026 release is primarily a business update with a limited results table. The headline development is that the FDA accepted the resubmitted NDA for oxylanthanum carbonate (OLC), with a PDUFA target action date of March 25, 2027. The company states that the June 2026 Complete Response Letter did not raise concerns about clinical efficacy or safety and did not request additional data. The resubmission includes CMC data from a new Drug Product manufacturing vendor, and the company says it does not know whether the FDA will conduct a pre-approval inspection of that vendor.
The reported financials show operating expenses moving in different directions. R&D fell to $2.2 million from $3.0 million, which the company attributes mainly to a $1.2 million decrease in development costs. G&A rose to $6.6 million from $4.4 million, with $1.4 million of that increase tied to commercial launch preparation and $0.6 million to non-cash stock-based compensation. Other income was $1.8 million, against $1.3 million a year earlier, and the company attributes it primarily to the change in fair value of its warrant liability. Net loss attributable to common stockholders was $(7.0) million, or $(0.25) per share, compared with $(6.0) million, or $(0.33) per share, a year earlier. The company attributes the wider loss primarily to commercial launch expenses.
No revenue, gross margin, operating loss, prior-quarter comparison or percentage change is printed in the document, so the quarter cannot be measured against sales or prior-quarter results. The release also reports no guidance, so there is no prior outlook to compare against. The per-share figures are reported as printed and are not reconciled further here.
On capital, the company reports $59 million of unaudited cash, cash equivalents and marketable securities as of September 30, 2026, and expects runway beyond 2027, including anticipated launch costs if OLC is approved. No capital returns are reported. The commercial readiness section describes planned hiring of commercial leaders in the first quarter of 2027, discussions with dialysis organizations, and the UniSource support hub. It also describes a CMS final rule for calendar year 2027 that establishes a $12.85 per-treatment addition to the base rate for phosphate binder funding effective January 1, 2027, which the company believes creates favorable launch conditions if OLC is approved. TDAPA eligibility is presented as the company's belief, subject to FDA classification and CMS confirmation.
Management, verbatim
We believe that the FDA’s acceptance of our NDA resubmission for OLC marks an important step toward our goal of bringing this much-needed treatment to patients
Shalabh Gupta, M.D., Chief Executive Officer
Not in the filing
stated, not guessed- No total revenue or product revenue is printed in the document.
- No cost of sales or gross margin is printed in the document.
- No total operating expenses or operating loss line is printed in the document.
- No percentage changes are printed for R&D, G&A, other income, net loss or net loss per share.
- No prior-quarter (Q2 2026) comparison figures are printed in the document.
- The document does not label the income statement lines as GAAP or non-GAAP, and no non-GAAP reconciliation is included; GAAP basis is used for reported income statement lines.
- No operating cash flow, free cash flow, total assets or stockholders' equity is printed in the document.
- No capital returns (share repurchases or dividends) are reported in the document.
- No financial guidance is provided, and no previous outlook was supplied for comparison.
- No segment or business-line revenue breakdown is printed in the document.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.